Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection.

Saved in:
Bibliographic Details
Title: Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection.
Authors: Cook JD; Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Hooey PB; Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada., Salazar KC; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., Clark JR; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., Jain U; Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada., Fernando C; Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada., Harvey H; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada., Cervantes A; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., Omagari S; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., Blankstein U; Department of Surgery, McMaster University, Hamilton, Ontario, Canada., Kropinski AM; Department of Pathobiology, University of Guelph, Ontario, Canada., Davidson AR; Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada., Maxwell KL; Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada., Burrows LL; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada., Terwilliger AL; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., Maresso AW; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA., German GJ; Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada. Electronic address: Gregory.German@unityhealth.to.
Source: International journal of antimicrobial agents [Int J Antimicrob Agents] 2025 Dec; Vol. 66 (6), pp. 107613. Date of Electronic Publication: 2025 Sep 08.
Publication Type: Journal Article; Case Reports
Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 9111860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7913 (Electronic) Linking ISSN: 09248579 NLM ISO Abbreviation: Int J Antimicrob Agents Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7913
DOI:10.1016/j.ijantimicag.2025.107613